Metsera, Inc. Prices Initial Public Offering at $18.00 per Share ...
22 hours ago · Metsera, Inc. prices its IPO at $18 per share, raising approximately $275 million to fund obesity treatments. Quiver AI Summary. Metsera, Inc., a clinical-stage biotechnology company specializing ...
Weight-loss drug developer Metsera raises $275 million in US IPO
22 hours ago · New York City-based Metsera sold 15.28 million shares above its targeted range at $18 apiece. The company had initially marketed 17.19 million shares at a range of $15 to $17 each.
Metsera, Maze go public with IPOs of $275M, $113M
9 hours ago · Metsera eyes $289M IPO to fund phase 3 weight loss trial. Meanwhile, Maze’s final share price fell squarely in the middle of the $15-$17 range it set out recently, while it raised the number of ...
Drugmakers Metsera and Maze Raise Combined $415 Million in …
21 hours ago · Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement Bloomberg Terminal It had offered 17.2 million shares for $15 to $17 each.
Metsera, Maze secure combined $415 million in IPOs
1 day ago · The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public. ... Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced Thursday. ...
Metsera Announces Pricing of Initial Public Offering
22 hours ago · In addition, Metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts ...
Two more biotechs, Metsera and Maze, cross IPO finish line
10 hours ago · Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.
Metsera Readies $275 Million IPO For Obesity Treatments
3 days ago · Metsera intends to raise $275 million in gross proceeds from an IPO of its common stock, offering approximately 17.19 million shares at a proposed midpoint price of $16.00 per share.
Metsera Seeks $289M Raise, $1.78B Valuation in IPO
4 days ago · Metsera is moving fast. Nine months post-launch and two weeks after announcing its plans for an IPO, the New York City–based weight-loss company said Monday that it is seeking a $1.78 billion valuation and a $250 million raise. Metsera is offering 17.19 million shares priced between $15 and $17. The raise could be as high as $289.1 million if the underwriters …
Nine-month-old obesity player Metsera files an IPO
4 days ago · Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.
- Some results have been removed